The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial.
Braido F, Melioli G, Candoli P, Cavalot A, Di Gioacchino M, Ferrero V, Incorvaia C, Mereu C, Ridolo E, Rolla G, Rossi O, Savi E, Tubino L, Reggiardo G, Baiardini I, di Marco E, Rinaldi G, Canonica GW; Lantigen Study Group; Accorsi C, Bossilino C, Bonzano L, DiLizia M, Fedrighini B, Garelli V, Gerace V, Maniscalco S, Massaro I, Messi A, Milanese M, Peveri S, Penno A, Pizzimenti S, Pozzo T, Raie A, Regina S, Sclifò F.
Braido F, et al. Among authors: canonica gw.
Immunol Lett. 2014 Dec;162(2 Pt B):185-93. doi: 10.1016/j.imlet.2014.10.026. Epub 2014 Nov 3.
Immunol Lett. 2014.
PMID: 25445613
Free PMC article.
Clinical Trial.